Nature Reviews Cardiology 7, 539 (October 2010) | doi:10.1038/nrcardio.2010.128
Antiplatelet therapy: Eptifibatide is noninferior to abciximab: implications for clinical practice
Alexandra King
Abstract
The glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors eptifibatide and abciximab have comparable efficacy and safety in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). These findings, from a randomized trial and a registry study, are reported in two papers published in the Journal of the American College of Cardiology (JACC).
|